SCHEMBL3497243

SCHEMBL3497243

CN1C(C)(C)CC(Nc2nc(Nc3cc4c(cc3Br)OC(F)(F)O4)ncc2F)CC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.47
ULK1 O75385 1/20 0.40
AURKB Q96GD4 2/20 0.36
AURKA O14965 1/20 0.36
CSNK2A2 P19784 3/20 0.36
CSNK2A1 P68400 3/20 0.36
ALK Q9UM73 4/20 0.34
KDR P35968 1/20 0.34
CYP3A4 P08684 1/20 0.34
SCN9A Q15858 1/20 0.34
SYK P43405 2/20 0.33
EGFR P00533 2/20 0.33
BTK Q06187 2/20 0.33
FLT3 P36888 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
GAS6 Q14393 1/20 0.33
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
PLK1 P53350 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494261 0.92 PRKCQ (0.49) PRKCQULK1AURKBAURKACSNK2A2
SCHEMBL3495124 0.86 PRKCQ (0.51) PRKCQULK1AURKBAURKACSNK2A2
SCHEMBL3495491 0.84 ULK1 (0.58) PRKCQULK1AURKBAURKAALK
SCHEMBL3497219 0.79 PRKCQ (0.54) PRKCQULK1AURKBAURKAALK
SCHEMBL3496422 0.79 PRKCQ (0.47) PRKCQULK1AURKBAURKACSNK2A2
SCHEMBL3496394 0.79 PRKCQ (0.55) PRKCQULK1AURKBAURKAALK
SCHEMBL3493344 0.79 PRKCQ (0.47) PRKCQULK1AURKBAURKACSNK2A2
SCHEMBL3493683 0.78 PRKCQ (0.57) PRKCQAURKBAURKAALKKDR
SCHEMBL3495520 0.78 PRKCQ (0.56) PRKCQAURKBAURKAALKKDR
SCHEMBL3495568 0.78 PRKCQ (0.56) PRKCQAURKAKDRSYKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP claimed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885ULK1 832/4885AURKB 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.